E346– Inner Voice – A Heartfelt Chat with Dr. Foojan and Dr. Kenneth Blum on Pre-Addition Assessment

Inner Voice - Heartfelt Chat with Dr. Foojan

E346– Inner Voice – A Heartfelt Chat with Dr. Foojan. In this episode, Dr. Foojan Zeine chats with Dr. Kenneth Blum, a well-known American scientist recognized for his work in psychopharmacology and psychiatric genetics. We explored the role of assessment of “Pre-Addiction” and the responsibility of the medical field to bring this important factor into everyday practice. Dr. Blum has published over 740 peer-reviewed articles, book chapters, and meeting abstracts, with 17 books with over 18,000 citations and 185,000 reads worldwide. He has distinguished himself and is credited with the first genetic association of the Dopamine D2 receptor gene and severe alcoholism, published in JAMA in 1990. He is considered by some to be the Father of Psychiatric Genetics. In 1995, Dr. Blum coined the term “Reward Deficiency Syndrome (RDS)” and developed the USA and foreign-patented “Genetic Addiction Risk Severity” (GARS) test. Dr. Blum has also developed patented Pro-dopamine regulators in the USA and Europe. His overall patent portfolio consists of 100 patents worldwide. Dr. Blum serves on 23 peer-reviewed journals and is the Editor-in-Chief of several academic journals, including Current Psychopharmacology and Addiction Psychiatry. He also serves as Associate Editor for Frontiers in Psychiatry and Frontiers in Public Health. Dr. Blum is also the founding President of the United Scientific Group, an academic publishing house. His work has been featured in all the major media outlets worldwide, and in 1990, his work on genetics was in the top 25 most important scientific discoveries by Discovery Magazine. He is the recipient of NIH grants and has been awarded Lifetime Achievements, distinguished Honorary Doctors of Humane Letters, Lifetime Honorary Professor at ELTE Eötvös Loránd University, Hungary, and Distinguished Honorary Professor at Adelson School of Medicine, Ariel University, Israel. Currently, besides faculty positions as an adjunct professor (Western University, University of Vermont, Wright School of Medicine), he is the Executive Chairman and CEO of TranspliceGen Therapeutics, Inc. Stanford University credited him in the top 2% of the World Best Scientist list (2023). Most recently, the International Research Awards on Neurology and Neuro Disorders awarded him the “Best Researcher Award 2023. Dr. Blum has been recently nominated for the KEIO Medical & Science PRIZE (THE JAPANESE EQUIVALENT TO THE NOBEL PRIZE) 2024. We have been selected as the #1 top podcast at FeedSpot 20 Best California Mental Health Podcasts https://podcasts.feedspot.com/california_mental_health_podcasts/ Check out my website: www.FoojanZeine.com, www.AwarenessIntegration.com, www.Foojan.com